Short Interest in Defence Therapeutics Inc. (OTCMKTS:DTCFF) Increases By 184.7%

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a large growth in short interest in August. As of August 14th, there was short interest totaling 4,359 shares, a growth of 184.7% from the July 30th total of 1,531 shares. Based on an average daily trading volume, of 7,971 shares, the short-interest ratio is presently 0.5 days.

Defence Therapeutics Trading Down 2.0%

OTCMKTS:DTCFF traded down $0.01 during trading hours on Friday, reaching $0.37. The company had a trading volume of 12,000 shares, compared to its average volume of 7,915. The business’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.38. Defence Therapeutics has a twelve month low of $0.25 and a twelve month high of $0.78.

About Defence Therapeutics

Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.

The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.